Clinical trial · Observational
Assessment of Geriatric Evaluations Impact on New AML Guidance
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML, Adult | Adult Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- Evaluate physiologic age using baseline measures of physical function, depression, cognition, frailty, and PROs in newly diagnosed AML patients receiving intensive and non-intensive treatment in relation to overall survival at 1 year.
- timeFrame
- At baseline, 14 days after treatment, 1 month after treatment
- description
- Short physical performance battery (SPPB), geriatric depression scale (GDS), mini-COG, patient reported outcomes of physical function, fatigue, depression, cognition, anxiety
- measure
- Evaluate baseline measures of physiologic age in relation to short term mortality
- timeFrame
- At 30 days and 60 days
- measure
- Evaluate baseline measures of physiologic age in relation to grade 3, 4, and 5 toxicities from treatment
- timeFrame
- At baseline, 14 days after treatment, 1 month after treatment
- measure
- Evaluate baseline measures of physiologic age in relation to complete remission
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy * New diagnosis being considered for new line of treatment * Age ≥ 50 years. * Performance status 0,1, and 2 Exclusion Criteria: * Inability to understand or unable to sign a written informed consent * Unable to fill out questionnaires on their own and/or do not have someone to help complete them
References
Publications (0)
Data not yet available